Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

by arresting mitosis and cell proliferation without impacting unrelated, normal cellular functions, thereby avoiding many of the toxicities commonly experienced by patients treated with existing anti-mitotic drugs.

About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics development efforts are directed to advancing multiple drug candidates through clinical trials to demonstrate proof-of-concept in humans, specifically in the areas of heart failure and cancer. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, recently entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. plan to conduct research with activators of cardiac myosin in order to identify potential treatments for patients with heart failure. Amgen has obtained an option for the joint development and commercialization of CK-1827452 exercisable during a defined period, the ending of which is dependent on Cytokinetics conduct of further clinical trials of CK-1827452. Cytokinetics cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Ispinesib has been the subject of a broad clinical trials program comprised of nine Phase II clinical trials as well as six Phase I or Ib clinical trials. Cytokinetics plans to conduct additional clinical trials with ispinesib and is conducting a Phase I/II trial of SB-74392
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:8/31/2015)... LAKE, N.J. and STAMFORD, Conn. ... U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue ... a worldwide collaboration agreement for the development and commercialization ... dual orexin receptor antagonist entering Phase III clinical development ... the terms of the agreement, Eisai and Purdue Pharma ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited (ASX:BNO, ... development of innovative therapeutics for the treatment of diseases ... announced that its BNC101 IND submission has passed review ... plans to initiate a Phase 1 clinical trial in ... metastatic pancreatic cancer prior to 31 December 2015. ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/wmn42n/prescription_pain ) has ... Drugs - Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ ... Opportunities: 2015 - 2020 Analysis and Forecasts" ... is defined as an unpleasant sensory and emotional ... At some point, everyone experiences pain. Pain may ...
Breaking Medicine Technology:Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
... announced that the U.S. Food and Drug Administration ... treatment of adult patients with glioblastoma multiforme (GBM) ...  The portable, wearable device delivers an anti-mitotic, anti-cancer ... The NovoTTF is a novel, first-in-class treatment option ...
... 2011 StelKast is proud to announce the ... Acetabular Liners. EXp™, a blend of antioxidant and ... consulting support of Steven Kurtz, Ph.D. and Exponent, ... clearance for large diameter cobalt-chrome femoral heads and ...
Cached Medicine Technology:FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 2FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 3FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 4A Better Acetabular Solution from StelKast ... Naturally 2
(Date:8/31/2015)... ... August 31, 2015 , ... ... include a wealth of information for specific translation services within the medical and ... an incredible track record of successful work. , ITC Global Translations specializes in ...
(Date:8/31/2015)... ... August 31, 2015 , ... India Network Foundation, a ... ” tool, which summarizes all available plans, plan maximums, pre-existing condition coverage limits ... to help India Network members make an informed decision regarding the care they ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... classes. , Starting September 1st they are offering pre and postnatal ... and "Healthy Body, Healthy Baby." , More information can be found at 248-601-6683. ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Sundance Film Festival award ... September 1. , “Alive Inside” shadows a social worker who advocates for the use ... a documentary about bringing music to residents in health care centers who may have ...
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... high quality, patient-oriented dental care. From the moment a patient arrives at the ... and Steven Tuckman will work with each and every patient to create a complete ...
Breaking Medicine News(10 mins):Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2
... ... SecureWorks®, Inc., a leading global provider of information security services ... at its healthcare clients doubled in the fourth quarter of 2009. ... per day in the first nine months of 2009 to an ...
... evolution a field that often deals with changes over ... disease in our lifetime? A lot, some scientists say. If ... on evolution in medical entrance and licensing exams, says an ... articles in the January 26 issue of Proceedings of ...
... technique to catch cancer early has taken an important ... NPL,s ,phantoms, will ensure an exciting new screening technique ... signs of cancer. The technique, Optical Coherence Tomography ... the surface of certain materials, notably human tissue. It ...
... Improved delivery of end-of-life care in prison is the ... of Nursing Research that has Penn State researchers working ... Department of Corrections. The project will develop an intervention ... the country. End-of-life care -- an attempt to optimize ...
... 26, 2010 A Universit de Montral research team is ... our brain to stop eating. "Mice deprived of leptin will ... moving around," says Mose Bendayan, a pathology professor at the ... leptin protein extensively. Leptin regulates appetite in mammals and ...
... ... is on a mission to meet Matt Lauer when he is in Vancouver to shoot ... ... fruit bars ( www.elevateme.com ) is on a mission to meet Matt Lauer when he ...
Cached Medicine News:Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 2Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 3Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 4Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 5Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 6Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 7Health News:Medical students may soon be tested on evolution 2Health News:Medical students may soon be tested on evolution 3Health News:New measurement technique will help in fight against cancer 2Health News:End-of-life care strategies examined in Pennsylvania prisons 2Health News:A gimmick-free weight-loss pill in the works 2Health News:Vancouver Company Must Meet Matt Lauer During Olympics 2
9mm Curved Blades with Sharp Pointed Tips; overall length 90mm; Stainless Steel....
Straight shaft with fine pointed 0.3mm Tips for Grasping Delicate Capsule; In Titanium....
Smooth colibri tip; In Titanium....
45 Degree Angle With 0.3, 12 Teeth with 5mm Tying Platform; In Titanium....
Medicine Products: